1	19 If felbamate is used as a concomitant AED subjects must be on felbamate for at least 2 years with a stable dose for 2 months or no less than 49 days prior to Visit 1 They must not have a history of white blood cell WBC count below 2500/?L 2.50 1E+09/L platelets below 100,000 liver function|felbamate[6,15]|||||||||C0060135|24812|24812|felbamate
1	19 If felbamate is used as a concomitant AED subjects must be on felbamate for at least 2 years with a stable dose for 2 months or no less than 49 days prior to Visit 1 They must not have a history of white blood cell WBC count below 2500/?L 2.50 1E+09/L platelets below 100,000 liver function|felbamate[65,74]|||||||2 years[88,95]||C0060135|24812|24812|felbamate
2	tests LFTs above 3 times the upper limit of normal ULN or other indication of hepatic or bone marrow dysfunction while receiving felbamate If subjects received felbamate in the past it must have been discontinued 2 months or no less than 49 days prior to Visit 1|felbamate[423,432]|||||||||C0060135|24812|24812|felbamate
2	tests LFTs above 3 times the upper limit of normal ULN or other indication of hepatic or bone marrow dysfunction while receiving felbamate If subjects received felbamate in the past it must have been discontinued 2 months or no less than 49 days prior to Visit 1|felbamate[454,463]|||||||2 months[507,515]||C0060135|24812|24812|felbamate
